OTC : CHEOY

Cochlear Limited

$41.98 USD

-$1.23 (-2.85%)

Volume
1.2K
Average Volume
81.26K
Market Capitalization
$5.49B
P/E Ratio
22.72
Dividend Yield
3.59%
Price Target
$117.00
Year High
$104.65
Year Low
$31.82
Day High
Day Low
Payout Ratio
$0.81
Current Ratio
$2.46
Company Overview

OTC

Diggory William Howitt

Medical - Devices

Healthcare

CHEOY

5500

AU

USD

61 2 9428 6555

191459205

N/A

Liquidity Metrics

0.22

2.46

1.44

0.33

0.81

Sales & Valuation

$2.34B

3.32

4.05

38.99

1.54

Profitability

$2.97

$388.9M

14.62%

19.28%

17.76%

12.36%

P/E Metrics

22.72

-3.47

-3.47

Analyst Price Target & Rating

$117.00

$117.00

$117.00

Neutral

3/5

0 Analysts

-64.12%

Financial Health Scores

9.23

5/9

$813.19M

$2.79B

$854.75M

$987.25M

Key Metrics (TTM)

$8.08B

3.42

14.26

2.46

17.76%

15.72%

4.40%

2.57%

$59.32

250 days

Company Executives
Name Title
Kristina Devon Vice President of Corporate Strategy & Investor Relations
Sarah Thom Chief Financial Officer
Dean Phizacklea Senior Vice President of Global Strategic Marketing
Jan Janssen Elec Chief Technology Officer
Rob McGrory Group General Counsel & Company Secretary
Stuart Sayers President of Asia Pacific & Latin America
Jennifer Hornery Senior Vice President of Global People & Culture
Jennifer Stevenson Vice President of Corporate Communications & Brand
Karen O'Driscoll Chief Information Officer
Diggory William Howitt Chief Executive Officer, MD, President & Executive Director
Poll Results

No votes yet today — be the first to share your view!

About Cochlear Limited (OTC:CHEOY) Stock

Cochlear Limited is a global healthcare company specializing in advanced auditory solutions. It develops and manufactures surgically implanted hearing devices for individuals of all ages, from children to adults, across the world. The company's diverse product range features cochlear implant systems, enhanced sound processor upgrades, bone conduction technology, and a variety of complementary accessories and related items. Founded in 1981, Cochlear Limited is headquartered in Sydney, Australia. ...

Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant

2026-07-14 09:17:00

Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 months White Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recognition score of 53.2% at their 12-month visits, up from a mean pre-implantation baseline of 15.2% — a 38.0 percentage point improvement.

Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants

2026-05-29 14:13:00

During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care LONE TREE, Colo., May 29, 2026 /PRNewswire/ -- May is Better Hearing and Speech Month, a month dedicated to raising awareness about the importance of hearing health.

Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant

2026-05-11 08:00:00

Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry Conferences White Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant. "The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted by the completion of enrollment in our pivotal clinical trial and the successful execution of a significant financing," said Brent Lucas, Chief Executive Officer of Envoy Medical.

Frequently Asked Questions

What is the current Cochlear Limited (CHEOY) stock price?

Cochlear Limited(OTC:CHEOY) stock price is $41.98 in the last trading session. During the trading session, CHEOY stock reached the peak price of $104.65 while $31.82 was the lowest point it dropped to. The percentage change in CHEOY stock occurred in the recent session was --2.85% while the dollar amount for the price change in CHEOY stock was -$1.23.

CHEOY's industry and sector of operation?

The OTC listed CHEOY is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of CHEOY?

Kristina Devon | Vice President of Corporate Strategy & Investor Relations
Sarah Thom | Chief Financial Officer
Dean Phizacklea | Senior Vice President of Global Strategic Marketing
Jan Janssen Elec | Chief Technology Officer
Rob McGrory | Group General Counsel & Company Secretary

How many employees does CHEOY have?

Number of CHEOY employees currently stands at 5500. CHEOY operates from 1 University Avenue, Sydney, NSW 2109, AU.

Link for CHEOY official website?

Official Website of CHEOY is: https://www.cochlear.com

How do I contact CHEOY?

CHEOY could be contacted at phone #61 2 9428 6555 and can also be accessed through its website. CHEOY operates from 1 University Avenue, Sydney, NSW 2109, AU.

How many shares of CHEOY are traded daily?

The average number of CHEOY shares traded daily for last 3 months was 81.26K.

What is the market cap of CHEOY currently?

The market value of CHEOY currently stands at $5.49B with its latest stock price at $41.98